Abstract

Exchange transfusions and phototherapy are used to treat hyperbilirubinemia, each method having its own disadvantages. Hemoperfusion with coated activated charcoal (CAC) produces low removal rates due to the strong binding of bilirubin to albumin. Biocompatible chemical agents were investigated to selectively unbind the bilirubin into solution just prior to CAC exposure. In batch mock solution tests, the addition of sodium benzoate resulted in a 69% equilibrium bilirubin removal at 50 mM and 96% removal at 100 mM. During flow tests, adsorptive removal of sodium benzoate was so rapid that the CAC had to be pretreated with sodium benzoate solutions. In the absence of sodium benzoate, the outlet bilirubin was 50% of the inlet concentration at the passage of one void volume, with a rapid increase to 70% (30% removal). With sodium benzoate at 100 mM, the same 50% outlet/inlet percent was observed at one void volume throughput, but the outlet concentration fell to 6% of the inlet at 12 column void volumes (94% removal). Similar experiments with bovine plasma/blood and human plasma resulted in an average increase in bilirubin removal of 25% for the bovine and human plasma and 35% for the bovine blood at 100 mM benzoate. A significant decrease in platelet aggregation was measured with the addition of sodium benzoate, which makes this augmented hemoperfusion removal of bilirubin clinically attractive.

Original languageEnglish (US)
Pages (from-to)585-589
Number of pages5
JournalASAIO Transactions
Volume34
Issue number3
StatePublished - 1988

Fingerprint

Sodium Benzoate
Hemoperfusion
Hyperbilirubinemia
Bilirubin
Charcoal
Sodium
Activated carbon
Plasma (human)
Blood
Phototherapy
Benzoates
Platelet Aggregation
Albumins
Platelets
Agglomeration
Throughput
Plasmas

ASJC Scopus subject areas

  • Biophysics

Cite this

Brian, B. F., Dorson, W. J., Pizziconi, V., Ramseyer, P. J., & Brooker, J. E. (1988). Augmented hemoperfusion for hyperbilirubinemia. ASAIO Transactions, 34(3), 585-589.

Augmented hemoperfusion for hyperbilirubinemia. / Brian, B. F.; Dorson, W. J.; Pizziconi, Vincent; Ramseyer, P. J.; Brooker, J. E.

In: ASAIO Transactions, Vol. 34, No. 3, 1988, p. 585-589.

Research output: Contribution to journalArticle

Brian, BF, Dorson, WJ, Pizziconi, V, Ramseyer, PJ & Brooker, JE 1988, 'Augmented hemoperfusion for hyperbilirubinemia', ASAIO Transactions, vol. 34, no. 3, pp. 585-589.
Brian BF, Dorson WJ, Pizziconi V, Ramseyer PJ, Brooker JE. Augmented hemoperfusion for hyperbilirubinemia. ASAIO Transactions. 1988;34(3):585-589.
Brian, B. F. ; Dorson, W. J. ; Pizziconi, Vincent ; Ramseyer, P. J. ; Brooker, J. E. / Augmented hemoperfusion for hyperbilirubinemia. In: ASAIO Transactions. 1988 ; Vol. 34, No. 3. pp. 585-589.
@article{73fac5b628d74b4cb0bd0e6b487fe9f9,
title = "Augmented hemoperfusion for hyperbilirubinemia",
abstract = "Exchange transfusions and phototherapy are used to treat hyperbilirubinemia, each method having its own disadvantages. Hemoperfusion with coated activated charcoal (CAC) produces low removal rates due to the strong binding of bilirubin to albumin. Biocompatible chemical agents were investigated to selectively unbind the bilirubin into solution just prior to CAC exposure. In batch mock solution tests, the addition of sodium benzoate resulted in a 69{\%} equilibrium bilirubin removal at 50 mM and 96{\%} removal at 100 mM. During flow tests, adsorptive removal of sodium benzoate was so rapid that the CAC had to be pretreated with sodium benzoate solutions. In the absence of sodium benzoate, the outlet bilirubin was 50{\%} of the inlet concentration at the passage of one void volume, with a rapid increase to 70{\%} (30{\%} removal). With sodium benzoate at 100 mM, the same 50{\%} outlet/inlet percent was observed at one void volume throughput, but the outlet concentration fell to 6{\%} of the inlet at 12 column void volumes (94{\%} removal). Similar experiments with bovine plasma/blood and human plasma resulted in an average increase in bilirubin removal of 25{\%} for the bovine and human plasma and 35{\%} for the bovine blood at 100 mM benzoate. A significant decrease in platelet aggregation was measured with the addition of sodium benzoate, which makes this augmented hemoperfusion removal of bilirubin clinically attractive.",
author = "Brian, {B. F.} and Dorson, {W. J.} and Vincent Pizziconi and Ramseyer, {P. J.} and Brooker, {J. E.}",
year = "1988",
language = "English (US)",
volume = "34",
pages = "585--589",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Augmented hemoperfusion for hyperbilirubinemia

AU - Brian, B. F.

AU - Dorson, W. J.

AU - Pizziconi, Vincent

AU - Ramseyer, P. J.

AU - Brooker, J. E.

PY - 1988

Y1 - 1988

N2 - Exchange transfusions and phototherapy are used to treat hyperbilirubinemia, each method having its own disadvantages. Hemoperfusion with coated activated charcoal (CAC) produces low removal rates due to the strong binding of bilirubin to albumin. Biocompatible chemical agents were investigated to selectively unbind the bilirubin into solution just prior to CAC exposure. In batch mock solution tests, the addition of sodium benzoate resulted in a 69% equilibrium bilirubin removal at 50 mM and 96% removal at 100 mM. During flow tests, adsorptive removal of sodium benzoate was so rapid that the CAC had to be pretreated with sodium benzoate solutions. In the absence of sodium benzoate, the outlet bilirubin was 50% of the inlet concentration at the passage of one void volume, with a rapid increase to 70% (30% removal). With sodium benzoate at 100 mM, the same 50% outlet/inlet percent was observed at one void volume throughput, but the outlet concentration fell to 6% of the inlet at 12 column void volumes (94% removal). Similar experiments with bovine plasma/blood and human plasma resulted in an average increase in bilirubin removal of 25% for the bovine and human plasma and 35% for the bovine blood at 100 mM benzoate. A significant decrease in platelet aggregation was measured with the addition of sodium benzoate, which makes this augmented hemoperfusion removal of bilirubin clinically attractive.

AB - Exchange transfusions and phototherapy are used to treat hyperbilirubinemia, each method having its own disadvantages. Hemoperfusion with coated activated charcoal (CAC) produces low removal rates due to the strong binding of bilirubin to albumin. Biocompatible chemical agents were investigated to selectively unbind the bilirubin into solution just prior to CAC exposure. In batch mock solution tests, the addition of sodium benzoate resulted in a 69% equilibrium bilirubin removal at 50 mM and 96% removal at 100 mM. During flow tests, adsorptive removal of sodium benzoate was so rapid that the CAC had to be pretreated with sodium benzoate solutions. In the absence of sodium benzoate, the outlet bilirubin was 50% of the inlet concentration at the passage of one void volume, with a rapid increase to 70% (30% removal). With sodium benzoate at 100 mM, the same 50% outlet/inlet percent was observed at one void volume throughput, but the outlet concentration fell to 6% of the inlet at 12 column void volumes (94% removal). Similar experiments with bovine plasma/blood and human plasma resulted in an average increase in bilirubin removal of 25% for the bovine and human plasma and 35% for the bovine blood at 100 mM benzoate. A significant decrease in platelet aggregation was measured with the addition of sodium benzoate, which makes this augmented hemoperfusion removal of bilirubin clinically attractive.

UR - http://www.scopus.com/inward/record.url?scp=0023724158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023724158&partnerID=8YFLogxK

M3 - Article

C2 - 3196567

AN - SCOPUS:0023724158

VL - 34

SP - 585

EP - 589

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -